Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials

Stauffer, Virginia; Ascher-Svanum, Haya; Lin Liu; Ball, Tamara; Conley, Robert
January 2009
BMC Psychiatry;2009, Vol. 9, Special section p1
Academic Journal
Background: How long an antipsychotic is effective in maintaining response is important in choosing the correct treatment for people with schizophrenia. This post-hoc analysis describes maintenance of response over 24 or 28 weeks in people treated for schizophrenia with olanzapine, risperidone, quetiapine, ziprasidone, or aripiprazole. Methods: This was a post-hoc analysis using data from 5 double-blind, randomized, comparative trials of 24 or 28 weeks duration in which olanzapine was compared to risperidone (1 study; N = 339), quetiapine (1 study; N = 346), ziprasidone (2 studies; N = 548 and 394) or aripiprazole (1 study; N = 566) for treatment of schizophrenia. For each study, time to loss of response in patients who met criteria for response at Week 8 and the proportion of patients who lost response following Week 8 were compared by treatment group. The number needed to treat (NNT) with olanzapine rather than comparator to avoid loss of one additional responder over 24 or 28 weeks of treatment was calculated for each study. Results: Time maintained in response was significantly longer (p < .05) for olanzapine compared to risperidone, quetiapine, and ziprasidone. Olanzapine did not significantly differ from aripiprazole. The proportion of patients who lost response was significantly lower for olanzapine versus risperidone, quetiapine, and ziprasidone (p < .05). NNTs to avoid one additional patient with loss of response with olanzapine versus risperidone, quetiapine and ziprasidone were favourable, ranging from 5 to 9. Conclusion: During 24 and 28 weeks of treatment, the antipsychotics studied differed in the time that treated patients with schizophrenia remained in response and the proportion of patients who lost response. Olanzapine treatment resulted in a consistent and statistically significant advantage in maintenance of response compared to treatment with risperidone, quetiapine and ziprasidone; but not compared to treatment with aripiprazole.


Related Articles

  • A unified framework for the evaluation of surrogate endpoints in mental-health clinical trials. Molenberghs, Geert; Burzykowski, Tomasz; Alonso, Ariel; Assam, Pryseley; Tilahun, Abel; Buyse, Marc // Statistical Methods in Medical Research;Jun2010, Vol. 19 Issue 3, p205 

    For a number of reasons, surrogate endpoints are considered instead of the so-called true endpoint in clinical studies, especially when such endpoints can be measured earlier, and/or with less burden for patient and experimenter. Surrogate endpoints may occur more frequently than their standard...

  • Quetiapine in the Long-Term Treatment of Schizophrenia.  // Child & Adolescent Psychopharmacology News;Aug2004, Vol. 9 Issue 5, p10 

    The article examines the long-term potency and safety of quetiapine in patients with schizophrenia using joint data from the open-label extension (OLE) of four Phase IIIa trials. The eligible patients that were selected for this study were from Europe, Canada and South Africa, and OLE phases...

  • Antipsychotic Polypharmacy Versus Monotherapy in Elderly Patients with Chronic Schizophrenia: A Clinical Trial. Mirabzadeh, Arash; Shemshadi, Hashem; Khodaei, Mohammad Reza; Sadighi, Gita; Hashempour, Sara; Mirabzadeh, Hossein; Biglarian, Akbar // Klinik Psikofarmakoloji Bulteni;2014, Vol. 24 Issue 4, p302 

    Objective: Antipsychotic polypharmacy in the elderly usually results in higher rates of interactions, side effects and increased cost. This research was designed to observe the benefits of replacing polypharmacy with a single medication in elderly patients with chronic schizophrenia. Methods:...

  • 'Cuddle chemical' promises to ease schizophrenia. Coghlan, Andy // New Scientist;7/17/2010, Vol. 207 Issue 2769, p01 

    The article discusses a clinical trial being conducted by David Feifel and team on the use of the hormone oxytocin to treat patients with schizophrenia.

  • Transforming Federal Policy.  // Health Affairs;May/Jun2009, Vol. 28 Issue 3, p760 

    The article discusses various reports published within the issue, including the effectiveness of Social Security Disability Insurance and Supplemental Security Income in mental health services, the advancement of medical technology to treat veterans with post-traumatic stress disorder and the...

  • Clinical trials in mental health. Dunn, Graham // Statistical Methods in Medical Research;Jun2010, Vol. 19 Issue 3, p203 

    The article discusses various reports published within the issue, including one by Geert Molenberghs and his colleagues on the evaluation of putative surrogates, one by Bibhas Chakraborty, Victor Strecher and Susan Murphy on optimal dynamic treatment regimes and one by Andrew Pickles and Tim...

  • Pharma: Clinic Roundup.  // BioWorld Today;7/12/2012, Vol. 23 Issue 134, p8 

    The article reports that Eli Lilly and Co.'s study H8Y-MC-HBBM investigating pomaglumetad methionil, also known as mGlu2/3, in patients with acute exacerbations of schizophrenia, has produced negative results.

  • Pharma: Clinic Roundup.  // BioWorld Today;8/30/2012, Vol. 23 Issue 169, p8 

    The article reports on the announcement by Eli Lilly and Co. of its decision to end ongoing trials testing of ongoing trials testing of promaglumetad methionil, also known as mGlu2/3, for the treatment of schizophrenia.

  • Ziprasidone good value for schizophrenia exacerbations.  // PharmacoEconomics & Outcomes News;8/25/2007, Issue 535, p1 

    The article focuses on an economic subanalysis of the Spanish ziprasidone vs haloperidol in sequential IM/Oral (ZIMO) treatment for schizophrenia exacerbations, conducted from a hospital perspective. The analysis included patients from the ZIMO database who had received sequential therapy with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics